dasapharm limited
dasapharm limited Company Information
Company Number
09325869
Website
dasapharm.comRegistered Address
2nd floor, 201 haverstock hill, london, NW3 4QG
Industry
Wholesale of pharmaceutical goods
Telephone
-
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
sia ratiobalt 50%
dmitri dan spivak 50%
dasapharm limited Estimated Valuation
Pomanda estimates the enterprise value of DASAPHARM LIMITED at £1.8m based on a Turnover of £2.7m and 0.65x industry multiple (adjusted for size and gross margin).
dasapharm limited Estimated Valuation
Pomanda estimates the enterprise value of DASAPHARM LIMITED at £48.3k based on an EBITDA of £9.4k and a 5.12x industry multiple (adjusted for size and gross margin).
dasapharm limited Estimated Valuation
Pomanda estimates the enterprise value of DASAPHARM LIMITED at £0 based on Net Assets of £-118.5k and 2.11x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Dasapharm Limited Overview
Dasapharm Limited is a live company located in london, NW3 4QG with a Companies House number of 09325869. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in November 2014, it's largest shareholder is sia ratiobalt with a 50% stake. Dasapharm Limited is a established, small sized company, Pomanda has estimated its turnover at £2.7m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Dasapharm Limited Health Check
Pomanda's financial health check has awarded Dasapharm Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
3 Regular
5 Weak
Size
annual sales of £2.7m, make it smaller than the average company (£25.8m)
- Dasapharm Limited
£25.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 7%, show it is growing at a faster rate (4.4%)
- Dasapharm Limited
4.4% - Industry AVG
Production
with a gross margin of 26.3%, this company has a comparable cost of product (26.3%)
- Dasapharm Limited
26.3% - Industry AVG
Profitability
an operating margin of 0.2% make it less profitable than the average company (4%)
- Dasapharm Limited
4% - Industry AVG
Employees
with 5 employees, this is below the industry average (38)
- Dasapharm Limited
38 - Industry AVG
Pay Structure
on an average salary of £72.2k, the company has an equivalent pay structure (£72.2k)
- Dasapharm Limited
£72.2k - Industry AVG
Efficiency
resulting in sales per employee of £541.3k, this is equally as efficient (£627.3k)
- Dasapharm Limited
£627.3k - Industry AVG
Debtor Days
it gets paid by customers after 82 days, this is later than average (59 days)
- Dasapharm Limited
59 days - Industry AVG
Creditor Days
its suppliers are paid after 66 days, this is slower than average (29 days)
- Dasapharm Limited
29 days - Industry AVG
Stock Days
it holds stock equivalent to 18 days, this is less than average (66 days)
- Dasapharm Limited
66 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 20 weeks, this is more cash available to meet short term requirements (12 weeks)
20 weeks - Dasapharm Limited
12 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 109.5%, this is a higher level of debt than the average (56.5%)
109.5% - Dasapharm Limited
56.5% - Industry AVG
DASAPHARM LIMITED financials
Dasapharm Limited's latest turnover from December 2022 is estimated at £2.7 million and the company has net assets of -£118.5 thousand. According to their latest financial statements, we estimate that Dasapharm Limited has 5 employees and maintains cash reserves of £529.4 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Nov 2015 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | ||||||||
| Interest Payable | ||||||||
| Interest Receivable | ||||||||
| Pre-Tax Profit | ||||||||
| Tax | ||||||||
| Profit After Tax | ||||||||
| Dividends Paid | ||||||||
| Retained Profit | ||||||||
| Employee Costs | ||||||||
| Number Of Employees | ||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Nov 2015 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 5,409 | 9,676 | 12,436 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 5,409 | 9,677 | 12,436 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 102,228 | 30,222 | 2,000 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 610,136 | 348,714 | 133,990 | 311,909 | 1,220,173 | 542,527 | 1 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 1,953 | 309 | 107 | 0 | 0 | 0 | 0 | 0 |
| Cash | 529,394 | 250,790 | 157,438 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 1,243,710 | 630,036 | 293,535 | 311,909 | 1,220,173 | 542,527 | 1 | 0 |
| total assets | 1,249,119 | 639,713 | 305,971 | 311,909 | 1,220,173 | 542,527 | 1 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 364,585 | 184,866 | 83,841 | 294,929 | 1,210,160 | 539,164 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 1,003,072 | 589,012 | 355,346 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 1,367,658 | 773,879 | 439,188 | 294,929 | 1,210,160 | 539,164 | 0 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 1,989 | 2,206 | 495 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 1,989 | 2,207 | 495 | 0 | 0 |
| total liabilities | 1,367,658 | 773,879 | 439,188 | 296,918 | 1,212,366 | 539,659 | 0 | 0 |
| net assets | -118,539 | -134,166 | -133,216 | 14,991 | 7,806 | 2,868 | 1 | 0 |
| total shareholders funds | -118,539 | -134,166 | -133,216 | 14,991 | 7,806 | 2,868 | 1 | 0 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Nov 2015 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | ||||||||
| Depreciation | 3,798 | 3,843 | 1,997 | 0 | 0 | 0 | 0 | |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | ||||||||
| Stock | 72,005 | 28,223 | 2,000 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 263,065 | 214,926 | -177,812 | -908,263 | 677,646 | 542,526 | 0 | 0 |
| Creditors | 179,720 | 101,025 | -211,088 | -915,231 | 670,996 | 539,164 | 0 | 0 |
| Accruals and Deferred Income | 414,060 | 233,666 | 353,357 | -217 | 1,711 | 495 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||
| interest | ||||||||
| cash flow from financing | ||||||||
| cash and cash equivalents | ||||||||
| cash | 278,604 | 93,352 | 157,438 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 278,604 | 93,352 | 157,438 | 0 | 0 | 0 | 0 | 0 |
dasapharm limited Credit Report and Business Information
Dasapharm Limited Competitor Analysis
Perform a competitor analysis for dasapharm limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
dasapharm limited Ownership
DASAPHARM LIMITED group structure
Dasapharm Limited has no subsidiary companies.
Ultimate parent company
DASAPHARM LIMITED
09325869
dasapharm limited directors
Dasapharm Limited currently has 2 directors. The longest serving directors include Mr Dimitri Mevzos (Jun 2015) and Mr Alexander Katzman (Jan 2016).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Dimitri Mevzos | England | 51 years | Jun 2015 | - | Director |
| Mr Alexander Katzman | England | 53 years | Jan 2016 | - | Director |
P&L
December 2022turnover
2.7m
+76%
operating profit
5.6k
0%
gross margin
26.3%
-1.13%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
-118.5k
-0.12%
total assets
1.2m
+0.95%
cash
529.4k
+1.11%
net assets
Total assets minus all liabilities
Similar Companies
dasapharm limited company details
company number
09325869
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
November 2014
age
10
accounts
Small Company
ultimate parent company
previous names
N/A
incorporated
UK
address
2nd floor, 201 haverstock hill, london, NW3 4QG
last accounts submitted
December 2022
dasapharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to dasapharm limited.
dasapharm limited Companies House Filings - See Documents
| date | description | view/download |
|---|
